Erasca initiates SEACRAFT-2 Phase 3 trial of naporafenib plus trametinib
PremiumThe FlyErasca initiates SEACRAFT-2 Phase 3 trial of naporafenib plus trametinib
5M ago
Erasca price target lowered to $5 from $8 at H.C. Wainwright
Premium
The Fly
Erasca price target lowered to $5 from $8 at H.C. Wainwright
6M ago
Erasca 86.5M share Secondary priced at $1.85
Premium
The Fly
Erasca 86.5M share Secondary priced at $1.85
6M ago
Erasca reports Q4 EPS (20c), consensus (23c)
PremiumThe FlyErasca reports Q4 EPS (20c), consensus (23c)
7M ago
ERAS Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
ERAS Earnings this Week: How Will it Perform?
8M ago
Capital One starts Erasca with Overweight into key data catalysts
Premium
The Fly
Capital One starts Erasca with Overweight into key data catalysts
8M ago
Erasca receives FDA Fast Track Designation for naporafenib
PremiumThe FlyErasca receives FDA Fast Track Designation for naporafenib
11M ago
Erasca price target lowered to $8 from $10 at H.C. Wainwright
Premium
The Fly
Erasca price target lowered to $8 from $10 at H.C. Wainwright
11M ago
Erasca achieves key milestones for naporafenib, ERAS-801
Premium
The Fly
Erasca achieves key milestones for naporafenib, ERAS-801
11M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100